Home » Newsletters » BioWorld Science

BioWorld Science

May 5, 2022

View Archived Issues

Shujing Biopharma, Jiangsu Nhwa Pharmaceutical patent 5-HT2A/DRD2 antagonists

Vertex Pharmaceuticals describes new CFTR modulators

New K(Ca) 1.1 channel activators identified at Gwangju Institute of Science and Technology

Dana-Farber Cancer Institute synthesizes SRPK1/SRPK2 inhibitors

Merck & Co. discovers diacylglycerol acyltransferase type 2 inhibitors

M1 mAChR antagonism attenuates opioid drug seeking behaviors in rat

TRAIL protein levels may predict response to acamprosate in alcohol use disorder

CDK7 inhibitor GTAEXS-617 shows potent antitumor activity in vivo

FDA awards orphan drug designation to AB-001 for pancreatic cancer and AML

ALTA-2530 shows preclinical efficacy as potential treatment of bronchiolitis obliterans syndrome

DGKk gene therapy rescues brain lipid profiles and long-term behavior in fragile X syndrome mice

Researchers discover HDAC1 as the cause of immune abnormalities in autistic mouse models

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...